MedKoo product information:

 Gemcitabine Hydrochloride

Gemcitabine hydrochloride is the hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Gemzar (gemcitabine for injection, USP) is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine HCl is 2´-deoxy-2´,2´-difluorocytidine monohydrochloride (β-isomer). The empirical formula for gemcitabine HCl is C9H11F2N3O4 •HCl. It has a molecular weight of 299.66. Gemcitabine HCl is a white to off-white solid. It is soluble in water, slightly soluble in methanol, and practically insoluble in ethanol and polar organic solvents. The clinical formulation is supplied in a sterile form for intravenous use only. Vials of Gemzar contain either 200 mg or 1 g of gemcitabine HCl (expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for Ph adjustment.

Mechanism of Action

Gemcitabine exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and also blocking the progression of cells through the G1/S-phase boundary. Gemcitabine is metabolized intracellularly by nucleoside kinases to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic effect of gemcitabine is attributed to a combination of two actions of the diphosphate and the triphosphate nucleosides, which leads to inhibition of DNA synthesis. First, gemcitabine diphosphate inhibits ribonucleotide reductase, which is responsible for catalyzing the reactions that generate the deoxynucleoside triphosphates for DNA synthesis. Inhibition of this enzyme by the diphosphate nucleoside causes a reduction in the concentrations of deoxynucleotides, including dCTP. Second, gemcitabine triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP (by the action of the diphosphate) enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabine nucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands. After this addition, there is inhibition of further DNA synthesis. DNA polymerase epsilon is unable to remove the gemcitabine nucleotide and repair the growing DNA strands (masked chain termination). In CEM T lymphoblastoid cells, gemcitabine induces internucleosomal DNA fragmentation, one of the characteristics of programmed cell death.

  1: Galmarini CM, Warren G, Senanayake MT, Vinogradov SV. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs. Int J Pharm. 2010 May 21. [Epub ahead of print] PubMed PMID: 20580798.

2: Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H. MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo. Mol Cancer Ther. 2010 Jun 22. [Epub ahead of print] PubMed PMID: 20571069.

3: Teicher BA. Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs. Curr Opin Pharmacol. 2010 May 21. [Epub ahead of print] PubMed PMID: 20547104.

4: Peters GJ, Hodzic J, Ortega B, Giovannetti E, Adema AD, Broekhuizen R, Kaspers GJ, Hubeek I. Methylation specific PCR to characterize methylation of the promoter of deoxycytidine kinase. Nucleosides Nucleotides Nucleic Acids. 2010 Jun;29(4-6):408-13. PubMed PMID: 20544528.

5: Koto K, Murata H, Kimura S, Horie N, Matsui T, Nishigaki Y, Ryu K, Sakabe T, Itoi M, Ashihara E, Maekawa T, Fushiki S, Kubo T. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep. 2010 Jul;24(1):233-9. PubMed PMID: 20514467.

6: Buranrat B, Prawan A, Kukongviriyapan U, Kongpetch S, Kukongviriyapan V. Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells. World J Gastroenterol. 2010 May 21;16(19):2362-70. PubMed PMID: 20480521; PubMed Central PMCID: PMC2874140.

7: Pili B, Bourgaux C, Amenitsch H, Keller G, Lepêtre-Mouelhi S, Desmaële D, Couvreur P, Ollivon M. Interaction of a new anticancer prodrug, gemcitabine-squalene, with a model membrane Coupled DSC and XRD study. Biochim Biophys Acta. 2010 Aug;1798(8):1522-1532. Epub 2010 May 7. PubMed PMID: 20435013.

8: Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010 Apr 15;70(8):3052-61. Epub 2010 Apr 13. PubMed PMID: 20388795.

9: Kountourakis P, Missitzis I, Doufexis D, Zobolas V, Pissakas G, Arnogiannaki N, Maliou S, Sotiropoulou A, Ardavanis A. Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer. J Cancer Res Clin Oncol. 2010 Apr 13. [Epub ahead of print] PubMed PMID: 20387073.

10: Garcia-Diaz M, Murray MS, Kunkel TA, Chou KM. Interaction between DNA Polymerase lambda and anticancer nucleoside analogs. J Biol Chem. 2010 May 28;285(22):16874-9. Epub 2010 Mar 26. PubMed PMID: 20348107; PubMed Central PMCID: PMC2878035.

11: Gofrit ON, Zorn KC, Shikanov S, Steinberg GD. Marker lesion experiments in bladder cancer--what have we learned? J Urol. 2010 May;183(5):1678-84. Epub 2010 Mar 17. Review. PubMed PMID: 20299042.

12: Kiew LV, Cheong SK, Sidik K, Chung LY. Improved plasma stability and sustained release profile of gemcitabine via polypeptide conjugation. Int J Pharm. 2010 May 31;391(1-2):212-20. Epub 2010 Mar 7. PubMed PMID: 20214970.

13: Lee DH, Iwanski GB, Thoennissen NH. Cucurbitacin: ancient compound shedding new light on cancer treatment. ScientificWorldJournal. 2010 Mar 5;10:413-8. Review. PubMed PMID: 20209387.

14: Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010 Apr;10(4):293-301. Epub 2010 Mar 4. Review. PubMed PMID: 20200537.

15: Paolino D, Cosco D, Racanicchi L, Trapasso E, Celia C, Iannone M, Puxeddu E, Costante G, Filetti S, Russo D, Fresta M. Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. J Control Release. 2010 Jun 1;144(2):144-50. Epub 2010 Feb 22. PubMed PMID: 20184929.

16: Philip PA. Novel targets for pancreatic cancer therapy. Surg Oncol Clin N Am. 2010 Apr;19(2):419-29. PubMed PMID: 20159523.

17: Tkaczuk KH. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther. 2009;31 Pt 2:2273-89. Review. PubMed PMID: 20110041.

18: Liu WM, Meyer B, Dalgleish AG. How immunotherapy can enhance the response to other modalities and improve outcome and quality of life. J BUON. 2009 Sep;14 Suppl 1:S103-9. Review. PubMed PMID: 19785052.

19: Bergman AM, Adema AD, Balzarini J, Bruheim S, Fichtner I, Noordhuis P, Fodstad O, Myhren F, Sandvold ML, Hendriks HR, Peters GJ. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs. 2010 Jan 12. [Epub ahead of print] PubMed PMID: 20066470.

20: Bandgar BP, Gawande SS, Bodade RG, Totre JV, Khobragade CN. Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, anti-inflammatory and antioxidant agents. Bioorg Med Chem. 2010 Feb;18(3):1364-70. Epub 2009 Dec 6. PubMed PMID: 20064725.

21: Harris P, Takeda A, Loveman E, Hartwell D. Time to full publication of studies of anticancer drugs for breast cancer, and the potential for publication bias. Int J Technol Assess Health Care. 2010 Jan;26(1):110-6. PubMed PMID: 20059788.

22: Walton MI, Eve PD, Hayes A, Valenti M, De Haven Brandon A, Box G, Boxall KJ, Aherne GW, Eccles SA, Raynaud FI, Williams DH, Reader JC, Collins I, Garrett MD. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther. 2010 Jan;9(1):89-100. Epub 2010 Jan 6. PubMed PMID: 20053762.

23: Ardavanis A, Kountourakis P, Karagiannis A, Doufexis D, Tzovaras AA, Rigatos G. Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer. Anticancer Res. 2009 Dec;29(12):5211-7. PubMed PMID: 20044638.

24: Zhang B, Shi ZL, Liu B, Yan XB, Feng J, Tao HM. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB. Anticancer Drugs. 2010 Mar;21(3):288-96. PubMed PMID: 20038829.

25: Saito Y, Yasunaga M, Kuroda J, Koga Y, Matsumura Y. Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour. Eur J Cancer. 2010 Feb;46(3):650-8. Epub 2009 Dec 16. PubMed PMID: 20015633.

26: Ishiura Y, Yamamoto H, Terasaki Y, Ishida Y, Fukushima W, Hirosawa H, Izumi R, Tanikawa F, Hayase H, Maruyama K, Obata C, Ishikawa M, Kasahara K, Fujimura M. [Analysis of factors associated with quality of life for older adult patients with non-small cell lung cancer receiving outpatient gemcitabine therapy as an alternative inpatient therapy]. Gan To Kagaku Ryoho. 2009 Dec;36(13):2565-9. Japanese. PubMed PMID: 20009456.

27: Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer. 2010 Jan;46(2):298-311. Epub 2009 Nov 28. Review. PubMed PMID: 19948396.

28: Barnett CM. Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer. Pharmacotherapy. 2009 Dec;29(12):1482-90. PubMed PMID: 19947807.

29: Smith V, Dai F, Spitz M, Peters GJ, Fiebig HH, Hussain A, Burger AM. Telomerase activity and telomere length in human tumor cells with acquired resistance to anticancer agents. J Chemother. 2009 Nov;21(5):542-9. PubMed PMID: 19933046.

30: Leelawat S, Leelawat K, Narong S, Matangkasombut O. The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti-invasion activity at low concentration and apoptosis induction at high concentration. Cancer Invest. 2010 May;28(4):357-63. PubMed PMID: 19916793.

31: Wang J, Lohman GJ, Stubbe J. Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5'-diphosphate. Biochemistry. 2009 Dec 15;48(49):11612-21. PubMed PMID: 19899807.

32: Abe K, Wakatsuki T, Katsushima F, Monoe K, Kanno Y, Takahashi A, Yokokawa J, Ohira H. A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy. World J Gastroenterol. 2009 Nov 7;15(41):5228-31. PubMed PMID: 19891026; PubMed Central PMCID: PMC2773906.

33: Couvreur P. ["Squalenoylation": a new approach to the design of anticancer and antiviral nanomedicines]. Bull Acad Natl Med. 2009 Mar;193(3):663-73; discussion 673-4. French. PubMed PMID: 19883017.

34: Bender DM, Bao J, Dantzig AH, Diseroad WD, Law KL, Magnus NA, Peterson JA, Perkins EJ, Pu YJ, Reutzel-Edens SM, Remick DM, Starling JJ, Stephenson GA, Vaid RK, Zhang D, McCarthy JR. Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J Med Chem. 2009 Nov 26;52(22):6958-61. PubMed PMID: 19860433.

35: Booth CM, Ohorodnyk P, Eisenhauer EA. Call for clarity in the reporting of benefit associated with anticancer therapies. J Clin Oncol. 2009 Nov 20;27(33):e213-4. Epub 2009 Oct 26. PubMed PMID: 19858370.

36: Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, Okusaka T, Yamagata S, Takahashi N, Hyodo I, Takaue Y, Heike Y. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol. 2009 Dec;39(12):797-806. Epub 2009 Oct 1. PubMed PMID: 19797418.

37: Bildstein L, Hillaireau H, Desmaële D, Lepêtre-Mouelhi S, Dubernet C, Couvreur P. Freeze-drying of squalenoylated nucleoside analogue nanoparticles. Int J Pharm. 2009 Nov 3;381(2):140-5. Epub 2009 Apr 11. PubMed PMID: 19782881.

38: Matsuzaki T, Yashiro M, Kaizaki R, Yasuda K, Doi Y, Sawada T, Ohira M, Hirakawa K. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci. 2009 Dec;100(12):2402-10. Epub 2009 Aug 18. PubMed PMID: 19764996.

39: Xia Y, Liu Y, Wan J, Wang M, Rocchi P, Qu F, Iovanna JL, Peng L. Novel triazole ribonucleoside down-regulates heat shock protein 27 and induces potent anticancer activity on drug-resistant pancreatic cancer. J Med Chem. 2009 Oct 8;52(19):6083-96. PubMed PMID: 19754200.

40: Jansen RS, Rosing H, Schellens JH, Beijnen JH. Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2',2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2009 Oct;23(19):3040-50. PubMed PMID: 19705384.

41: Arias JL, Reddy LH, Couvreur P. Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. J Drug Target. 2009 Sep;17(8):586-98. PubMed PMID: 19694612.

42: Kausar T, Ahsan A, Hasan MR, Lin L, Beer DG, Ralhan R. Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines. Int J Cancer. 2010 Mar 15;126(6):1494-503. PubMed PMID: 19685492.

43: Saif MW, Oettle H, Vervenne WL, Thomas JP, Spitzer G, Visseren-Grul C, Enas N, Richards DA. Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer J. 2009 Jul-Aug;15(4):339-43. PubMed PMID: 19672152.

44: He J, Ying W, Yang H, Xu X, Shao W, Guan Y, Jiang M, Wu Y, Zhong B, Wang D, Tucker S, Zhong N. Gemcitabine plus cisplatin chemotherapy with concurrent para-toluenesulfonamide local injection therapy for peripherally advanced nonsmall cell lung cancer larger than 3 cm in the greatest dimension. Anticancer Drugs. 2009 Oct;20(9):838-44. PubMed PMID: 19668080.

45: Uwagawa T, Chiao PJ, Gocho T, Hirohara S, Misawa T, Yanaga K. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. Anticancer Res. 2009 Aug;29(8):3173-8. PubMed PMID: 19661331.

46: Higashiyama M, Oda K, Okami J, Maeda J, Kodama K, Imamura F, Minamikawa K, Takano T, Kobayashi H. Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients. Lung Cancer. 2010 Jun;68(3):472-7. Epub 2009 Aug 5. PubMed PMID: 19660825.

47: Reddy LH, Renoir JM, Marsaud V, Lepetre-Mouelhi S, Desmaële D, Couvreur P. Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor. Mol Pharm. 2009 Sep-Oct;6(5):1526-35. PubMed PMID: 19634915.

48: Abu-Baker SO. Gemcitabine impacts histological structure of mice testis and embryonic organs. Pak J Biol Sci. 2009 Apr 15;12(8):607-15. PubMed PMID: 19634485.

49: Azuma H, Yamamoto K, Inamoto T, Ibuki N, Kotake Y, Sakamoto T, Kiyama S, Ubai T, Takahara K, Segawa N, Narumi Y, Katsuoka Y. Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. Am J Clin Oncol. 2009 Dec;32(6):592-606. PubMed PMID: 19593084.

50: Lagisetty P, Vilekar P, Awasthi V. Synthesis of radiolabeled cytarabine conjugates. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4764-7. Epub 2009 Jun 17. PubMed PMID: 19574048.

51: Rolff J, Dorn C, Merk J, Fichtner I. Response of Patient-Derived Non-Small Cell Lung Cancer Xenografts to Classical and Targeted Therapies Is Not Related to Multidrug Resistance Markers. J Oncol. 2009;2009:814140. Epub 2009 Jun 14. PubMed PMID: 19547715; PubMed Central PMCID: PMC2696640.

52: Modrak DE, Leon E, Goldenberg DM, Gold DV. Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines. Mol Cancer Res. 2009 Jun;7(6):890-6. Epub 2009 Jun 16. PubMed PMID: 19531570.

53: Nuhn P, Künzli BM, Hennig R, Mitkus T, Ramanauskas T, Nobiling R, Meuer SC, Friess H, Berberat PO. Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo. Mol Cancer. 2009 Jun 9;8:37. PubMed PMID: 19508729; PubMed Central PMCID: PMC2702301.

54: Shord SS, Patel SR. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines. J Exp Clin Cancer Res. 2009 Jun 6;28:76. PubMed PMID: 19500405; PubMed Central PMCID: PMC2708129.

55: McNeill DR, Lam W, DeWeese TL, Cheng YC, Wilson DM 3rd. Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol Cancer Res. 2009 Jun;7(6):897-906. Epub 2009 May 26. PubMed PMID: 19470598; PubMed Central PMCID: PMC2745049.

56: Tamaro I, Genazzani A, Canonico P, Grosa G. Lack of in vitro interactions using human liver microsomes between rabeprazole and anticancer drugs. Eur J Drug Metab Pharmacokinet. 2009 Jan-Mar;34(1):19-26. PubMed PMID: 19462924.

57: Fushiki H, Kanoh-Azuma T, Katoh M, Kawabata K, Jiang J, Tsuchiya N, Satow A, Tamai Y, Hayakawa Y. Quantification of mouse pulmonary cancer models by microcomputed tomography imaging. Cancer Sci. 2009 Aug;100(8):1544-9. Epub 2009 May 13. PubMed PMID: 19459854.

58: Hauswald S, Duque-Afonso J, Wagner MM, Schertl FM, Lübbert M, Peschel C, Keller U, Licht T. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res. 2009 Jun 1;15(11):3705-15. Epub 2009 May 19. PubMed PMID: 19458058.

59: Grinberg O, Gedanken A, Patra CR, Patra S, Mukherjee P, Mukhopadhyay D. Sonochemically prepared BSA microspheres containing Gemcitabine, and their potential application in renal cancer therapeutics. Acta Biomater. 2009 Oct;5(8):3031-7. Epub 2009 May 13. PubMed PMID: 19442766.

60: Zhao WP, Zhu B, Duan YZ, Chen ZT. Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells. Oncol Rep. 2009 Jun;21(6):1405-11. PubMed PMID: 19424617.

61: Mamaghani S, Patel S, Hedley DW. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer. 2009 Apr 30;9:132. PubMed PMID: 19405981; PubMed Central PMCID: PMC2685435.

62: Ceresa C, Giovannetti E, Voortman J, Laan AC, Honeywell R, Giaccone G, Peters GJ. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells. Mol Cancer Ther. 2009 Apr 21. [Epub ahead of print] PubMed PMID: 19383850.

63: Hoffman RM. Dual-color imaging of tumor angiogenesis. Methods Mol Biol. 2009;515:45-61. PubMed PMID: 19378118.

64: VanderPorten EC, Taverna P, Hogan JN, Ballinger MD, Flanagan WM, Fucini RV. The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther. 2009 Apr;8(4):930-9. PubMed PMID: 19372566.

65: Lissoni P, Rovelli F, Brivio F, Zago R, Colciago M, Messina G, Mora A, Porro G. A randomized study of chemotherapy versus biochemotherapy with chemotherapy plus Aloe arborescens in patients with metastatic cancer. In Vivo. 2009 Jan-Feb;23(1):171-5. PubMed PMID: 19368145.

66: Silasi DA, Alvero AB, Rutherford TJ, Brown D, Mor G. Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opin Pharmacother. 2009 Apr;10(6):1059-67. Review. Erratum in: Expert Opin Pharmacother. 2009 Jun;10(8):1387. PubMed PMID: 19364253.

67: Horn L, Sandler AB. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S7-16. Review. PubMed PMID: 19362948.

68: Lammers T, Subr V, Ulbrich K, Peschke P, Huber PE, Hennink WE, Storm G. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials. 2009 Jul;30(20):3466-75. Epub 2009 Mar 21. PubMed PMID: 19304320.

69: Saif MW, Tytler E, Lansigan F, Brown DM, Husband AJ. Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. Expert Opin Investig Drugs. 2009 Apr;18(4):469-79. Review. PubMed PMID: 19278301.

70: Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, Lluch A, Llombart A, du Bois A, Kreienberg R, Mayordomo JI, Antón A, Harrison M, Jones A, Carrasco E, Vaury AT, Frimodt-Moller B, Fumoleau P. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol. 2009 Apr 10;27(11):1753-60. Epub 2009 Mar 9. PubMed PMID: 19273714.

71: Miyanaga N, Akaza H. [Urological cancer]. Gan To Kagaku Ryoho. 2009 Feb;36(2):193-8. Japanese. PubMed PMID: 19223735.

72: Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR, Halldén G. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res. 2009 Mar 1;15(5):1730-40. Epub 2009 Feb 17. PubMed PMID: 19223497; PubMed Central PMCID: PMC2873675.

73: Xie Q, Jia L, Liu YH, Wei CG. Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo. World J Gastroenterol. 2009 Feb 14;15(6):737-41. PubMed PMID: 19222100; PubMed Central PMCID: PMC2653444.

74: Hayashi Y, Kuriyama H, Umezu H, Tanaka J, Yoshimasu T, Furukawa T, Tanaka H, Kagamu H, Gejyo F, Yoshizawa H. Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cell lung cancer. Intern Med. 2009;48(4):203-8. Epub 2009 Feb 16. PubMed PMID: 19218769.

75: Govindarajan R, Leung GP, Zhou M, Tse CM, Wang J, Unadkat JD. Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G910-22. Epub 2009 Jan 22. PubMed PMID: 19164483; PubMed Central PMCID: PMC2670673.

76: Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, Dinsart C, Herrmann A, Balboni G, Rommelaere J, Raykov Z. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res. 2009 Jan 15;15(2):511-9. PubMed PMID: 19147756.

77: Smith V, Wirth GJ, Fiebig HH, Burger AM. Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents. Cancer Genomics Proteomics. 2008 Sep-Oct;5(5):263-73. PubMed PMID: 19129557.

78: Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009 Jan 1;69(1):178-84. PubMed PMID: 19118001; PubMed Central PMCID: PMC2745904.

79: Priya PL, Shanmughavel P. A docking model of human ribonucleotide reductase with flavin and phenosafranine. Bioinformation. 2009 Sep 30;4(3):123-6. PubMed PMID: 20198185; PubMed Central PMCID: PMC2828892.

80: Launay-Vacher V, Isnard-Bagnis C, Janus N, Karie S, Deray G. [Chemotherapy and renal toxicity]. Bull Cancer. 2008 May 28;95 FMC Onco:F96-103. French. PubMed PMID: 18511375.

81: Benizri F, Bonan B, Ferrio AL, Brandely ML, Castagné V, Théou-Anton N, Verlinde-Carvalho M, Havard L. Stability of antineoplastic agents in use for home-based intravenous chemotherapy. Pharm World Sci. 2009 Feb;31(1):1-13. Epub 2008 Dec 10. Review. PubMed PMID: 19067224.

82: Hu Y, Zhou T, Liao Q, Zhang TP, Chen G, Zhao YP. [Establishing the method of collagen-gel droplet embedded culture drug sensitivity test with rat tail collagen]. Zhonghua Wai Ke Za Zhi. 2008 Jul 1;46(13):998-1001. Chinese. PubMed PMID: 19035202.

83: Benhadji KA, Serova M, Ghoul A, Cvitkovic E, Le Tourneau C, Ogbourne SM, Lokiec F, Calvo F, Hammel P, Faivre S, Raymond E. Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells. Br J Cancer. 2008 Dec 2;99(11):1808-15. PubMed PMID: 19034280; PubMed Central PMCID: PMC2600681.

84: Noma B, Sasaki T, Fujimoto Y, Serikawa M, Kobayashi K, Inoue M, Itsuki H, Kamigaki M, Minami T, Chayama K. Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int J Oncol. 2008 Dec;33(6):1187-94. PubMed PMID: 19020751.

85: Lekas A, Papathomas TG, Papatsoris AG, Deliveliotis C, Lazaris AC. Novel therapeutics in metastatic bladder cancer. Expert Opin Investig Drugs. 2008 Dec;17(12):1889-99. Review. PubMed PMID: 19012504.

86: Nishime C, Ohnishi Y, Suemizu H, Tamaoki N, Kusumi T, Sato F, Yamazaki H, Nakamura M, Ueyama Y, Kijima H. In vivo chemotherapeutic profile of human gallbladder small cell carcinoma. Biomed Res. 2008 Oct;29(5):251-6. PubMed PMID: 18997440.

87: Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res. 2008 Nov 1;14(21):6790-6. PubMed PMID: 18980972; PubMed Central PMCID: PMC2690708.

88: Xinopoulos D, Dimitroulopoulos D, Karanikas I, Fotopoulou A, Oikonomou N, Korkolis D, Kouroumalis E, Antsaklis G, Vassilopoulos P, Paraskevas E. Gemcitabine as palliative treatment in patients with unresectable pancreatic cancer previously treated with placement of a covered metal stent. A randomized controlled trial. J BUON. 2008 Jul-Sep;13(3):341-7. PubMed PMID: 18979547.

89: Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, Okusaka T, Ikeda M, Morizane C, Yamamoto N, Yoshida T, Kamatani N, Furuse J, Ishii H, Saijo N, Ozawa S, Sawada J. Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). Drug Metab Pharmacokinet. 2008;23(5):379-84. PubMed PMID: 18974616.

90: Launay-Vacher V, Etessami R, Janus N, Spano JP, Ray-Coquard I, Oudard S, Gligorov J, Pourrat X, Beuzeboc P, Deray G, Morere JF; Renal Insufficiency Anticancer Medications (IRMA) Study Group. Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung. 2009 Jan-Feb;187(1):69-74. Epub 2008 Oct 22. PubMed PMID: 18941834.

91: Lissoni P, Messina G, Parolini D, Balestra A, Brivio F, Fumagalli L, Vigore L, Rovelli F. A spiritual approach in the treatment of cancer: relation between faith score and response to chemotherapy in advanced non-small cell lung cancer patients. In Vivo. 2008 Sep-Oct;22(5):577-81. PubMed PMID: 18853749.

92: Galmarini CM, Warren G, Kohli E, Zeman A, Mitin A, Vinogradov SV. Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines. Mol Cancer Ther. 2008 Oct;7(10):3373-80. PubMed PMID: 18852140; PubMed Central PMCID: PMC2593126.

93: Kurtzberg LS, Battle T, Rouleau C, Bagley RG, Agata N, Yao M, Schmid S, Roth S, Crawford J, Krumbholz R, Ewesuedo R, Yu XJ, Wang F, Lavoie EJ, Teicher BA. Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors. Mol Cancer Ther. 2008 Oct;7(10):3212-22. PubMed PMID: 18852125.

94: Bernhaus A, Ozsvar-Kozma M, Saiko P, Jaschke M, Lackner A, Grusch M, Horvath Z, Madlener S, Krupitza G, Handler N, Erker T, Jaeger W, Fritzer-Szekeres M, Szekeres T. Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells. Invest New Drugs. 2009 Oct;27(5):393-401. Epub 2008 Oct 8. PubMed PMID: 18841326.

95: Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A, Mattern J, Li Z, Kolb A, Moldenhauer G, Altevogt P, Wirth T, Werner J, Schemmer P, Büchler MW, Salnikov AV, Herr I. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut. 2009 Jul;58(7):949-63. Epub 2008 Oct 1. PubMed PMID: 18829980.

96: Reddy LH, Ferreira H, Dubernet C, Mouelhi SL, Desmaele D, Rousseau B, Couvreur P. Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms. Anticancer Drugs. 2008 Nov;19(10):999-1006. PubMed PMID: 18827565.

97: Béghin A, Matera EL, Brunet-Manquat S, Dumontet C. Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line. Cell Cycle. 2008 Oct;7(19):3074-82. Epub 2008 Oct 12. PubMed PMID: 18818514.

98: Ozensoy Guler O, Arslan O, Kockar F. Differential in vitro inhibitory effects of anticancer drugs on tumor-associated carbonic anhydrase isozymes CA IX and CA XII. Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):335-40. PubMed PMID: 18806891.

99: de Wolf C, Jansen R, Yamaguchi H, de Haas M, van de Wetering K, Wijnholds J, Beijnen J, Borst P. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102. Epub 2008 Sep 2. PubMed PMID: 18765824.

100: Hou J, Wang D, Zhang R, Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res. 2008 Sep 1;14(17):5519-30. PubMed PMID: 18765544.

101: Yamamoto K, Mizutani Y, Nakanishi H, Fujiwara J, Ishida H, Toiyama D, Abe K, Hayashi I, Okada K, Kawauchi A, Mizuno M, Yoshida J, Miki T. Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma. Int J Oncol. 2008 Sep;33(3):565-71. PubMed PMID: 18695887.

102: Cheng T. Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond. Curr Opin Support Palliat Care. 2008 Sep;2(3):153-60. Review. PubMed PMID: 18685414.

103: Ea S, Giacometti S, Ciccolini J, Akhmedjanova V, Aubert C. Cytotoxic effects of haplamine and its major metabolites on human cancer cell lines. Planta Med. 2008 Aug;74(10):1265-8. Epub 2008 Jul 29. PubMed PMID: 18666046.

104: Tham LS, Wang L, Soo RA, Lee SC, Lee HS, Yong WP, Goh BC, Holford NH. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clin Cancer Res. 2008 Jul 1;14(13):4213-8. PubMed PMID: 18594002.

105: Pérez-Torras S, García-Manteiga J, Mercadé E, Casado FJ, Carbó N, Pastor-Anglada M, Mazo A. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. Biochem Pharmacol. 2008 Aug 1;76(3):322-9. Epub 2008 May 20. PubMed PMID: 18589402.

106: Pinho MB, Costas F, Sellos J, Dienstmann R, Andrade PB, Herchenhorn D, Peixoto FA, Santos VO, Small IA, Guimarães DP, Ferreira CG. XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy. Urol Oncol. 2009 Jul-Aug;27(4):382-90. Epub 2008 Jun 16. PubMed PMID: 18555708.

107: Arias JL, Reddy LH, Couvreur P. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting. Langmuir. 2008 Jul 15;24(14):7512-9. Epub 2008 Jun 10. PubMed PMID: 18540685.

108: Boukovinas I, Souglakos J, Hatzidaki D, Kakolyris S, Ziras N, Vamvakas L, Polyzos A, Geroyianni A, Agelidou A, Agelaki S, Kalbakis K, Kotsakis A, Mavroudis D, Georgoulias V. Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study. Lung Cancer. 2009 Jan;63(1):77-82. Epub 2008 May 27. PubMed PMID: 18508158.

109: Skoda C, Erovic BM, Wachek V, Vormittag L, Wrba F, Martinek H, Heiduschka G, Kloimstein P, Selzer E, Thurnher D. Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck. Oncol Rep. 2008 Jun;19(6):1499-503. PubMed PMID: 18497956.

110: Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, Terrosi C, Mannucci S, Giorgi G, Francini G, Cusi MG. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother. 2008 Feb-Mar;31(2):132-47. PubMed PMID: 18481383.

111: Reddy LH, Khoury H, Paci A, Deroussent A, Ferreira H, Dubernet C, Declèves X, Besnard M, Chacun H, Lepêtre-Mouelhi S, Desmaële D, Rousseau B, Laugier C, Cintrat JC, Vassal G, Couvreur P. Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice. Drug Metab Dispos. 2008 Aug;36(8):1570-7. Epub 2008 May 12. PubMed PMID: 18474674.

112: Reddy LH, Couvreur P. Novel approaches to deliver gemcitabine to cancers. Curr Pharm Des. 2008;14(11):1124-37. Review. PubMed PMID: 18473859.

113: Lissoni P, Messina G, Balestra A, Colciago M, Brivio F, Fumagalli L, Fumagalli G, Parolini D. Efficacy of cancer chemotherapy in relation to synchronization of cortisol rhythm, immune status and psychospiritual profile in metastatic non-small cell lung cancer. In Vivo. 2008 Mar-Apr;22(2):257-62. PubMed PMID: 18468412.

114: Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008 Sep;19(9):1592-9. Epub 2008 May 7. PubMed PMID: 18467316.

115: Correale P, Fioravanti A, Bertoldi I, Montagnani F, Miracco C, Francini G. Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen. J Chemother. 2008 Apr;20(2):278-81. PubMed PMID: 18467257.

116: Dean-Colomb W, Esteva FJ. Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Semin Oncol. 2008 Apr;35(2 Suppl 2):S31-8; quiz S40. Review. PubMed PMID: 18410797.

117: Han SS, Choi SH, Lee YK, Kim JW, Park NH, Song YS, Lee HP, Kang SB. Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer. Cancer Invest. 2008 May;26(4):426-30. PubMed PMID: 18443964.

118: Istomin YP, Zhavrid EA, Alexandrova EN, Sergeyeva OP, Petrovich SV. Dose enhancement effect of anticaner drugs associated with increased temperature in vitro. Exp Oncol. 2008 Mar;30(1):56-9. PubMed PMID: 18438342.

119: Pirollo KF, Rait A, Zhou Q, Zhang XQ, Zhou J, Kim CS, Benedict WF, Chang EH. Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo. Clin Cancer Res. 2008 Apr 1;14(7):2190-8. PubMed PMID: 18381961.

120: Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders M, Wang S, Buhrow SA, Safgren SL, Yaszemski MJ, Reid JM, Ames MM, Mukherjee P, Mukhopadhyay D. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 2008 Mar 15;68(6):1970-8. PubMed PMID: 18339879.

121: Paolino D, Cosco D, Licciardi M, Giammona G, Fresta M, Cavallaro G. Polyaspartylhydrazide copolymer-based supramolecular vesicular aggregates as delivery devices for anticancer drugs. Biomacromolecules. 2008 Apr;9(4):1117-30. Epub 2008 Feb 29. PubMed PMID: 18307306.

122: Epstein RJ, Leung TW. Tumor resensitization to erlotinib following brief substitution of cetuximab. Cancer Chemother Pharmacol. 2008 Nov;62(6):1111-2. Epub 2008 Feb 19. PubMed PMID: 18283460.

123: Ishikawa T, Kamimura H, Tsuchiya A, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Takeda K, Kamimura T. Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer. Hepatogastroenterology. 2007 Dec;54(80):2378-82. PubMed PMID: 18265669.

124: Reddy LH, Marque PE, Dubernet C, Mouelhi SL, Desmaële D, Couvreur P. Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine. J Pharmacol Exp Ther. 2008 May;325(2):484-90. Epub 2008 Feb 7. PubMed PMID: 18258784.

125: Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, Ma H, Li X, Yang Z, Hoffman RM, Ammons WS, Hart CP, Matteucci M. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem. 2008 Apr 24;51(8):2412-20. Epub 2008 Feb 8. PubMed PMID: 18257544.

126: Couvreur P, Reddy LH, Mangenot S, Poupaert JH, Desmaële D, Lepêtre-Mouelhi S, Pili B, Bourgaux C, Amenitsch H, Ollivon M. Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue. Small. 2008 Feb;4(2):247-53. PubMed PMID: 18247384.

127: Jordheim LP, Galmarini CM, Dumontet C. Recent developments to improve the efficacy of cytotoxic nucleoside analogues. Recent Pat Anticancer Drug Discov. 2006 Jun;1(2):163-70. Review. PubMed PMID: 18221034.

128: Xiong ZP, Zhang YD, Huang F, Liang ZY. [Transhepatic arterial chemoembolization with gemcitabine and carboplatin for the treatment of stage III hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi. 2007 Aug;29(8):623-5. Chinese. PubMed PMID: 18210886.

129: Danzinger S, Filipits M. [Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC)]. Wien Med Wochenschr. 2007;157(21-22):554-61. Review. German. PubMed PMID: 18157593.

130: Oliveras-Ferraros C, Vazquez-Martin A, Colomer R, De Llorens R, Brunet J, Menendez JA. Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling. Int J Oncol. 2008 Jan;32(1):113-20. PubMed PMID: 18097549.

131: Lissoni P, Fumagalli L, Brivio F, Rovelli F, Messina G, Di Fede G, Colciago M, Brera G. Cancer chemotherapy-induced lymphocytosis: a revolutionary discovery in the medical oncology. J Biol Regul Homeost Agents. 2006 Jan-Jun;20(1-2):29-35. PubMed PMID: 18088552.

132: Zambelli A, Prada GA, Fregoni V, Ponchio L, Sagrada P, Pavesi L. Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy. Lung Cancer. 2008 Jun;60(3):455-7. Epub 2007 Dec 11. PubMed PMID: 18063195.

133: Le Tourneau C, Raymond E, Faivre S. Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison. Curr Pharm Des. 2007;13(33):3427-39. Review. PubMed PMID: 18045196.

134: Lin ZZ, Hsu C, Chang YC, Yu CJ, Hsu CH, Lin CC, Cheng AL, Yang PC, Yang CH. Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment. Lung Cancer. 2008 May;60(2):215-21. Epub 2007 Nov 19. PubMed PMID: 18022277.

135: Jiang X, Galettis P, Links M, Mitchell PL, McLachlan AJ. Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. Br J Clin Pharmacol. 2008 Mar;65(3):326-33. Epub 2007 Oct 24. PubMed PMID: 17961191; PubMed Central PMCID: PMC2291243.

136: Herst PM, Petersen T, Jerram P, Baty J, Berridge MV. The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Biochem Pharmacol. 2007 Dec 3;74(11):1587-95. Epub 2007 Aug 19. PubMed PMID: 17904534.

137: Reddy LH, Dubernet C, Mouelhi SL, Marque PE, Desmaele D, Couvreur P. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release. 2007 Dec 4;124(1-2):20-7. Epub 2007 Aug 23. PubMed PMID: 17878060.

138: Specenier PM, Van den Weyngaert D, Van Laer C, Weyler J, Van den Brande J, Huizing MT, Dyck J, Schrijvers D, Vermorken JB. Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data. Ann Oncol. 2007 Nov;18(11):1856-60. Epub 2007 Sep 6. PubMed PMID: 17823386.

139: Lacouture ME, Melosky BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett. 2007 Jul-Aug;12(6):1-5. Review. PubMed PMID: 17762902.

140: Baradari V, Höpfner M, Huether A, Schuppan D, Scherübl H. Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol. 2007 Sep 7;13(33):4458-66. PubMed PMID: 17724801.

141: Ikeda O, Tamura Y, Nakasone Y, Shiraishi S, Kawanaka K, Tomiguchi S, Yamashita Y, Takamori H, Kanemitsu K, Baba H. Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma. Cardiovasc Intervent Radiol. 2007 Sep-Oct;30(5):912-21. Epub 2007 Aug 21. PubMed PMID: 17710478.

142: Ardavanis A, Kountourakis P, Maliou S, Vassilakopoulou M, Basioukas S, Kyriakou F, Koumna S, Rigatos G. Gemcitabine and oral vinorelbine as salvage treatment in patients with advanced anthracycline- and taxane-pretreated breast cancer. Anticancer Res. 2007 Jul-Aug;27(4C):2989-92. PubMed PMID: 17695483.

143: Schimmel KJ, Gelderblom H, Guchelaar HJ. Cyclopentenyl cytosine (CPEC): an overview of its in vitro and in vivo activity. Curr Cancer Drug Targets. 2007 Aug;7(5):504-9. Review. PubMed PMID: 17691910.

144: Selvaggi G, Scagliotti GV. Perspectives in adjuvant chemotherapy in NSCLC. Expert Rev Respir Med. 2007 Aug;1(1):99-110. PubMed PMID: 20477270.

145: Van Quaquebeke E, Mahieu T, Dumont P, Dewelle J, Ribaucour F, Simon G, Sauvage S, Gaussin JF, Tuti J, El Yazidi M, Van Vynckt F, Mijatovic T, Lefranc F, Darro F, Kiss R. 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de] isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity. J Med Chem. 2007 Aug 23;50(17):4122-34. Epub 2007 Jul 21. PubMed PMID: 17658777.

146: Stella B, Arpicco S, Rocco F, Marsaud V, Renoir JM, Cattel L, Couvreur P. Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. Int J Pharm. 2007 Nov 1;344(1-2):71-7. Epub 2007 Jun 14. PubMed PMID: 17651931.

147: Serova M, Galmarini CM, Ghoul A, Benhadji K, Green SR, Chiao J, Faivre S, Cvitkovic E, Le Tourneau C, Calvo F, Raymond E. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Br J Cancer. 2007 Sep 3;97(5):628-36. Epub 2007 Jul 17. PubMed PMID: 17637678; PubMed Central PMCID: PMC2360357.

148: Li C, Gemma A, Minegishi Y, Matsuda K, Seike Y, Noro R, Shionoya A, Kawakami A, Ogawa N, Kudoh S. In vitro simulation study of individualized chemotherapy in lung cancer. J Nippon Med Sch. 2007 Jun;74(3):217-22. PubMed PMID: 17625370.

149: Sandrini MP, Clausen AR, On SL, Aarestrup FM, Munch-Petersen B, Piskur J. Nucleoside analogues are activated by bacterial deoxyribonucleoside kinases in a species-specific manner. J Antimicrob Chemother. 2007 Sep;60(3):510-20. Epub 2007 Jul 5. PubMed PMID: 17615154.

150: Gang J, Park SB, Hyung W, Choi EH, Wen J, Kim HS, Shul YG, Haam S, Song SY. Magnetic poly epsilon-caprolactone nanoparticles containing Fe3O4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model. J Drug Target. 2007 Jul;15(6):445-53. PubMed PMID: 17613663.

151: Lang DS, Droemann D, Schultz H, Branscheid D, Martin C, Ressmeyer AR, Zabel P, Vollmer E, Goldmann T. A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy. Respir Res. 2007 Jun 14;8:43. PubMed PMID: 17567922; PubMed Central PMCID: PMC1913052.

152: Nio Y, Toga T, Maruyama R, Fukushima M. Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy. Oncol Rep. 2007 Jul;18(1):59-64. PubMed PMID: 17549346.

153: Welch SA, Moore MJ. Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer. Future Oncol. 2007 Jun;3(3):247-54. Review. PubMed PMID: 17547518.

154: Toschi L, Finocchiaro G, Ceresoli GL, Zucali PA, Cavina R, Garassino I, De Vincenzo F, Santoro A, Cappuzzo F. Is gemcitabine cost effective in cancer treatment? Expert Rev Pharmacoecon Outcomes Res. 2007 Jun;7(3):239-49. PubMed PMID: 20528311.

155: Sandrini MP, Shannon O, Clausen AR, Björck L, Piskur J. Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria. Antimicrob Agents Chemother. 2007 Aug;51(8):2726-32. Epub 2007 May 25. PubMed PMID: 17526755; PubMed Central PMCID: PMC1932510.

156: Wuttig D, Kunze D, Fuessel S, Toma M, Stade J, Kotzsch M, Kappler M, Taubert H, Schwenzer B, Baretton G, Hakenberg OW, Meye A, Wirth MP. Are overexpressed alternative survivin transcripts in human bladder cancer suitable targets for siRNA-mediated in vitro inhibition? Int J Oncol. 2007 Jun;30(6):1317-24. PubMed PMID: 17487351.

157: Castelli F, Sarpietro MG, Rocco F, Ceruti M, Cattel L. Interaction of lipophilic gemcitabine prodrugs with biomembrane models studied by Langmuir-Blodgett technique. J Colloid Interface Sci. 2007 Sep 1;313(1):363-8. Epub 2007 Apr 13. PubMed PMID: 17485098.

158: Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris). 2007 Apr-May;55(3-4):201-4. Epub 2007 Apr 18. PubMed PMID: 17446010.

159: Apparaju SK, Gudelsky GA, Desai PB. Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis. Cancer Chemother Pharmacol. 2008 Feb;61(2):223-9. Epub 2007 Apr 19. PubMed PMID: 17443325.

160: Li XM, Lévi F. Circadian physiology is a toxicity target of the anticancer drug gemcitabine in mice. J Biol Rhythms. 2007 Apr;22(2):159-66. PubMed PMID: 17440217.

161: Yoneda S. [Outpatient chemotherapy for lung cancer]. Gan To Kagaku Ryoho. 2007 Apr;34(4):533-7. Japanese. PubMed PMID: 17431337.

162: Kirstein MN, Brundage RC, Moore MM, Williams BW, Hillman LA, Dagit JW, Fisher JE, Marker PH, Kratzke RA, Yee D. Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system. Cancer Chemother Pharmacol. 2008 Feb;61(2):291-9. Epub 2007 Apr 12. PubMed PMID: 17429628.

163: Lucchi M, Chella A, Melfi F, Dini P, Tibaldi C, Fontanini G, Mussi A. Four-modality therapy in malignant pleural mesothelioma: a phase II study. J Thorac Oncol. 2007 Mar;2(3):237-42. PubMed PMID: 17410047.

164: Moon YW, Choi SH, Kim YT, Sohn JH, Chang J, Kim SK, Park MS, Chung KY, Lee HJ, Kim JH. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer. 2007 May 1;109(9):1829-35. PubMed PMID: 17366594.

165: Sottani C, Turci R, Schierl R, Gaggeri R, Barbieri A, Violante FS, Minoia C. Simultaneous determination of gemcitabine, taxol, cyclophosphamide and ifosfamide in wipe samples by high-performance liquid chromatography/tandem mass spectrometry: protocol of validation and uncertainty of measurement. Rapid Commun Mass Spectrom. 2007;21(7):1289-96. PubMed PMID: 17340557.

166: Wang H, Wang Y, Rayburn ER, Hill DL, Rinehart JJ, Zhang R. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol. 2007 Apr;30(4):947-53. PubMed PMID: 17332934.

167: Li M, Zhang Z, Hill DL, Wang H, Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 2007 Mar 1;67(5):1988-96. PubMed PMID: 17332326.

168: Satraplatin: BMS 182751, BMY 45594, JM 216. Drugs R D. 2007;8(2):125-32. Review. PubMed PMID: 17324011.

169: Li YF, Fu S, Hu W, Liu JH, Finkel KW, Gershenson DM, Kavanagh JJ. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer. 2007 Jul-Aug;17(4):739-63. Epub 2007 Feb 16. Review. PubMed PMID: 17309673.

170: Calvagno MG, Celia C, Paolino D, Cosco D, Iannone M, Castelli F, Doldo P, Frest M. Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes. Curr Drug Deliv. 2007 Jan;4(1):89-101. PubMed PMID: 17269921.

171: Horie N, Murata H, Kimura S, Takeshita H, Sakabe T, Matsui T, Maekawa T, Kubo T, Fushiki S. Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J Cancer. 2007 Jan 29;96(2):255-61. PubMed PMID: 17242698; PubMed Central PMCID: PMC2360011.

172: Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007 Jan 15;67(2):792-801. PubMed PMID: 17234791.

173: Korpanty G, Carbon JG, Grayburn PA, Fleming JB, Brekken RA. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res. 2007 Jan 1;13(1):323-30. PubMed PMID: 17200371.

174: El-Rayes BF, Gadgeel S, Shields AF, Manza S, Lorusso P, Philip PA. Phase I study of bryostatin 1 and gemcitabine. Clin Cancer Res. 2006 Dec 1;12(23):7059-62. PubMed PMID: 17145828.

175: Castelli F, Sarpietro MG, Ceruti M, Rocco F, Cattel L. Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry. Mol Pharm. 2006 Nov-Dec;3(6):737-44. PubMed PMID: 17140261.

176: Cicero G, Fulfaro F, Caraceni A, Arcara C, Badalamenti G, Intrivici C, Gebbia N. A case of Guillain-Barré syndrome in a patient with non small cell lung cancer treated with chemotherapy. J Chemother. 2006 Jun;18(3):325-7. PubMed PMID: 17129846.

177: Amoh Y, Nagakura C, Maitra A, Moossa AR, Katsuoka K, Hoffman RM, Bouvet M. Dual-color imaging of nascent angiogenesis and its inhibition in liver metastases of pancreatic cancer. Anticancer Res. 2006 Sep-Oct;26(5A):3237-42. PubMed PMID: 17094435.

178: Couvreur P, Stella B, Reddy LH, Hillaireau H, Dubernet C, Desmaële D, Lepêtre-Mouelhi S, Rocco F, Dereuddre-Bosquet N, Clayette P, Rosilio V, Marsaud V, Renoir JM, Cattel L. Squalenoyl nanomedicines as potential therapeutics. Nano Lett. 2006 Nov;6(11):2544-8. PubMed PMID: 17090088.

179: Verma A, Wang H, Manavathi B, Fok JY, Mann AP, Kumar R, Mehta K. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res. 2006 Nov 1;66(21):10525-33. PubMed PMID: 17079475.

180: Matsuo R, Kondo T, Ohshiro Y, Moon Y, Yamamoto Y, Takeshima T, Todoroki T, Ohkohchi N. [A case of stage IVA intrahepatic biliary tract cancer successfully treated with gemcitabine]. Gan To Kagaku Ryoho. 2006 Oct;33(10):1501-4. Japanese. PubMed PMID: 17033247.

181: Duraj J, Bodo J, Sulikova M, Rauko P, Sedlak J. Diverse resveratrol sensitization to apoptosis induced by anticancer drugs in sensitive and resistant leukemia cells. Neoplasma. 2006;53(5):384-92. PubMed PMID: 17013532.

182: Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, Needham R, Guo J, Gordon M, Chung N, Warrener P, Jackson AL, Carleton M, Oatley M, Locco L, Santini F, Smith T, Kunapuli P, Ferrer M, Strulovici B, Friend SH, Linsley PS. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol. 2006 Dec;26(24):9377-86. Epub 2006 Sep 25. PubMed PMID: 17000754; PubMed Central PMCID: PMC1698535.

183: Wehbe H, Henson R, Lang M, Meng F, Patel T. Pifithrin-alpha enhances chemosensitivity by a p38 mitogen-activated protein kinase-dependent modulation of the eukaryotic initiation factor 4E in malignant cholangiocytes. J Pharmacol Exp Ther. 2006 Dec;319(3):1153-61. Epub 2006 Sep 18. PubMed PMID: 16982703.

184: Stapleton S, Blaney S. New agents for intrathecal administration. Cancer Invest. 2006 Aug-Sep;24(5):528-34. Review. PubMed PMID: 16939963.

185: El-Mabhouh AA, Angelov CA, Cavell R, Mercer JR. A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer. Nucl Med Biol. 2006 Aug;33(6):715-22. PubMed PMID: 16934690.

186: Shao J, Zhou B, Chu B, Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets. 2006 Aug;6(5):409-31. Review. PubMed PMID: 16918309.

187: Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006 Aug 1;12(15):4652-61. PubMed PMID: 16899615.

188: Nakamura K, Yamaguchi T, Sudo K, Ishihara T, Saisho H. [Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer]. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:219-23. Japanese. PubMed PMID: 16898006.

189: Zhang X, Yashiro M, Ren J, Hirakawa K. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep. 2006 Sep;16(3):563-8. PubMed PMID: 16865256.

190: Ogura Y, Mizumoto K, Tanaka M, Ohuchida K, Murakami M, Yamada D, Ishikawa N, Nagai E. Strategy for prevention of local recurrence of pancreatic cancer after pancreatectomy: antitumor effect of gemcitabine mixed with fibrin glue in an orthotopic nude mouse model. Surgery. 2006 Jul;140(1):66-71. PubMed PMID: 16857444.

191: Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther. 2006 Jun;5(6):1387-95. Review. PubMed PMID: 16818496.

192: Marcé S, Molina-Arcas M, Villamor N, Casado FJ, Campo E, Pastor-Anglada M, Colomer D. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica. 2006 Jul;91(7):895-902. PubMed PMID: 16818276.

193: Gemma A, Li C, Sugiyama Y, Matsuda K, Seike Y, Kosaihira S, Minegishi Y, Noro R, Nara M, Seike M, Yoshimura A, Shionoya A, Kawakami A, Ogawa N, Uesaka H, Kudoh S. Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database. BMC Cancer. 2006 Jun 30;6:174. PubMed PMID: 16813650; PubMed Central PMCID: PMC1533844.

194: Giovannetti E, Danesi R, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M. In vitro studies on gemcitabine combinations with other antiblastics. Ann Oncol. 2006 May;17 Suppl 5:v17-19. Review. PubMed PMID: 16807450.

195: Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PH, Schellens JH. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur J Clin Pharmacol. 2006 Aug;62(8):681-4. Epub 2006 Jun 24. PubMed PMID: 16799820.

196: Sekine I, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Saijo N, Tamura T. Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer. 2006 Aug;53(2):157-64. Epub 2006 Jun 15. PubMed PMID: 16781004.

197: Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics. 2006 Jun;16(6):429-38. PubMed PMID: 16708051.

198: Takizawa M, Kawakami K, Obata T, Matsumoto I, Ohta Y, Oda M, Sasaki T, Watanabe G. In vitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer. Oncol Rep. 2006 Jun;15(6):1533-9. PubMed PMID: 16685392.

199: Shiah HS, Cheng AL, Hsu C, Hsu CH, Liu TW, Chang JY, Jan CM, Chao Y, Yu WL, Chuang TR, Whang-Peng J, Chen LT. Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. J Gastroenterol Hepatol. 2006 Mar;21(3):531-6. PubMed PMID: 16638094.

200: Natsume T, Watanabe J, Horiuchi T, Kobayashi M. Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs. Anticancer Res. 2006 Mar-Apr;26(2A):1145-51. PubMed PMID: 16619516.

201: Christensen LA, Finch RA, Booker AJ, Vasquez KM. Targeting oncogenes to improve breast cancer chemotherapy. Cancer Res. 2006 Apr 15;66(8):4089-94. PubMed PMID: 16618728.

202: Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006 Aug;32(6):676-81. Epub 2006 Apr 17. Review. PubMed PMID: 16616827.

203: Chen YW, Cleaver JE, Hanaoka F, Chang CF, Chou KM. A novel role of DNA polymerase eta in modulating cellular sensitivity to chemotherapeutic agents. Mol Cancer Res. 2006 Apr;4(4):257-65. PubMed PMID: 16603639.

204: Piacentini P, Donadelli M, Costanzo C, Moore PS, Palmieri M, Scarpa A. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch. 2006 Jun;448(6):797-804. Epub 2006 Mar 28. PubMed PMID: 16568310.

205: Thottassery JV, Westbrook L, Someya H, Parker WB. c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-beta-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. Mol Cancer Ther. 2006 Feb;5(2):400-10. PubMed PMID: 16505115.

206: Mizutani Y, Nakamura T, Nomoto T, Kawauchi A, Miki T. [Progress in therapy for testicular tumors]. Gan To Kagaku Ryoho. 2006 Feb;33(2):183-7. Review. Japanese. PubMed PMID: 16484853.

207: Scagliotti GV, Selvaggi G. Antimetabolites and cancer: emerging data with a focus on antifolates. Expert Opin Ther Pat. 2006 Feb;16(2):189-200. PubMed PMID: 20144046.

208: Kandagal PB, Ashoka S, Seetharamappa J, Shaikh SM, Jadegoud Y, Ijare OB. Study of the interaction of an anticancer drug with human and bovine serum albumin: spectroscopic approach. J Pharm Biomed Anal. 2006 May 3;41(2):393-9. Epub 2006 Jan 18. PubMed PMID: 16413740.

209: Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, Lathia C, Petrenciuc O, Moore MJ. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res. 2006 Jan 1;12(1):144-51. PubMed PMID: 16397036.

210: Nakazawa H, Yoshihara S, Kudo D, Morohashi H, Kakizaki I, Kon A, Takagaki K, Sasaki M. 4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells. Cancer Chemother Pharmacol. 2006 Jan;57(2):165-70. Epub 2005 Sep 15. PubMed PMID: 16341905.

211: de Lange SM, van der Born K, Kroep JR, Jensen HA, Pfeiffer P, Cleverly A, van Groeningen CJ, Peters GJ. No evidence of gemcitabine accumulation during weekly administration. Eur J Clin Pharmacol. 2005 Dec;61(11):843-9. Epub 2005 Nov 10. PubMed PMID: 16283278.

212: Colomer R. Gemcitabine in combination with paclitaxel for the treatment of metastatic breast cancer. Womens Health (Lond Engl). 2005 Nov;1(3):323-9. PubMed PMID: 19803874.

213: Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF, Mori M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 2006 Mar;24(3):506-13. Epub 2005 Oct 20. PubMed PMID: 16239320.

214: Klein A, He X, Roche M, Mallett A, Duska L, Supko JG, Seiden MV. Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy. Gynecol Oncol. 2006 Jan;100(1):205-9. Epub 2005 Sep 19. PubMed PMID: 16171852.

215: Rostock M, Huber R, Greiner T, Fritz P, Scheer R, Schueler J, Fiebig HH. Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. Anticancer Res. 2005 May-Jun;25(3B):1969-75. PubMed PMID: 16158932.

216: Pearce HL, Alice Miller M. The evolution of cancer research and drug discovery at Lilly Research Laboratories. Adv Enzyme Regul. 2005;45:229-55. Epub 2005 Sep 6. PubMed PMID: 16143373.

217: Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park). 2005 Jul;19(8):1057-63; discussion 1063-4, 1069. Review. PubMed PMID: 16131047.

218: Ishii H, Furuse J, Kinoshita T, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Nakachi K, Suzuki E, Yoshino M. Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine. Jpn J Clin Oncol. 2005 Sep;35(9):526-30. Epub 2005 Aug 24. PubMed PMID: 16120621.

219: Bellone G, Novarino A, Chiappino I, Gramigni C, Carbone A, Addeo A, Tonel E, Bertetto O, Emanuelli G. Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy. Anticancer Res. 2005 Sep-Oct;25(5):3287-91. PubMed PMID: 16101140.

220: Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol. 2005 Dec 10;23(35):8950-8. Epub 2005 Aug 1. PubMed PMID: 16061910.

221: Perry WL 3rd, Shepard RL, Sampath J, Yaden B, Chin WW, Iversen PW, Jin S, Lesoon A, O'Brien KA, Peek VL, Rolfe M, Shyjan A, Tighe M, Williamson M, Krishnan V, Moore RE, Dantzig AH. Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005 Aug 1;65(15):6593-600. PubMed PMID: 16061639.

222: Bocci G, Fioravanti A, Orlandi P, Bernardini N, Collecchi P, Del Tacca M, Danesi R. Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer. 2005 Aug 8;93(3):319-30. PubMed PMID: 16052215; PubMed Central PMCID: PMC2361561.

223: Dranitsaris G, Evans WK, Milliken D, Zanke B. The impact of practice guidelines and funding policies on the use of new drugs in advanced non-small cell lung cancer. J Eval Clin Pract. 2005 Aug;11(4):350-6. PubMed PMID: 16011647.

224: Voss C, Eyol E, Berger MR. Identification of potent anticancer activity in Ximenia americana aqueous extracts used by African traditional medicine. Toxicol Appl Pharmacol. 2006 Mar 15;211(3):177-87. Epub 2005 Jul 11. PubMed PMID: 16005923.

225: Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J. Chemotherapy for non-small cell lung cancer in elderly patients. Chest. 2005 Jul;128(1):132-9. PubMed PMID: 16002926.

226: Andres R, Mayordomo JI, Lara R, Lastra R, Ortega E, Polo E, Lambea J, Isla D, Saenz-Cusi A, Escudero P, Tres A. Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer. 2005 Jun;6(2):158-62. PubMed PMID: 16001994.

227: Dauer M, Herten J, Bauer C, Renner F, Schad K, Schnurr M, Endres S, Eigler A. Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells. J Immunother. 2005 Jul-Aug;28(4):332-42. PubMed PMID: 16000951.

228: Vikhanskaya F, Siddique MM, Kei Lee M, Broggini M, Sabapathy K. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin Cancer Res. 2005 Jun 15;11(12):4348-56. PubMed PMID: 15958617.

229: Shanks RH, Rizzieri DA, Flowers JL, Colvin OM, Adams DJ. Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. Clin Cancer Res. 2005 Jun 1;11(11):4225-33. PubMed PMID: 15930361.

230: Dell'Erba C, Chiavarina B, Fenoglio C, Petrillo G, Cordazzo C, Boncompagni E, Spinelli D, Ognio E, Aiello C, Mariggiò MA, Viale M. Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene in gastrointestinal tumour cell lines and preliminary evaluation of its toxicity in vivo. Pharmacol Res. 2005 Sep;52(3):271-82. PubMed PMID: 15921920.

231: Kazuno H, Sakamoto K, Fujioka A, Fukushima M, Matsuda A, Sasaki T. Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line. Cancer Sci. 2005 May;96(5):295-302. PubMed PMID: 15904471.

232: Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, Künzli B, Autschbach F, Meuer S, Büchler MW, Friess H. Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res. 2005 May 15;11(10):3790-8. PubMed PMID: 15897578.

233: Johnsamuel J, Eriksson S, Oliveira M, Tjarks W. Docking simulation with a purine nucleoside specific homology model of deoxycytidine kinase, a target enzyme for anticancer and antiviral therapy. Bioorg Med Chem. 2005 Jul 1;13(13):4160-7. PubMed PMID: 15876539.

234: Sehouli J. Review of gemcitabine-based combinations for platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:23-30. Review. PubMed PMID: 15839955.

235: Loprevite M, Tiseo M, Grossi F, Scolaro T, Semino C, Pandolfi A, Favoni R, Ardizzoni A. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res. 2005;15(1):39-48. PubMed PMID: 15839304.

236: Kim I, Song X, Vig BS, Mittal S, Shin HC, Lorenzi PJ, Amidon GL. A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol Pharm. 2004 Mar-Apr;1(2):117-27. PubMed PMID: 15832508.

237: Ardavanis AS, Ioannidis GN, Rigatos GA. Acute myopathy in a patient with lung adenocarcinoma treated with gemcitabine and docetaxel. Anticancer Res. 2005 Jan-Feb;25(1B):523-5. PubMed PMID: 15816622.

238: Song X, Lorenzi PL, Landowski CP, Vig BS, Hilfinger JM, Amidon GL. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm. 2005 Mar-Apr;2(2):157-67. PubMed PMID: 15804190.

239: Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer. 2005 Sep 1;116(3):458-63. PubMed PMID: 15800950.

240: Castelli F, Raudino A, Fresta M. A mechanistic study of the permeation kinetics through biomembrane models: gemcitabine-phospholipid bilayer interaction. J Colloid Interface Sci. 2005 May 1;285(1):110-7. PubMed PMID: 15797403.

241: Alexander RL, Greene BT, Torti SV, Kucera GL. A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms. Cancer Chemother Pharmacol. 2005 Jul;56(1):15-21. Epub 2005 Mar 24. PubMed PMID: 15789226.

242: Aydemir N, Celikler S, Bilaloğlu R. In vitro genotoxic effects of the anticancer drug gemcitabine in human lymphocytes. Mutat Res. 2005 Apr 4;582(1-2):35-41. PubMed PMID: 15781208.

243: Yau CY, Wheeler JJ, Sutton KL, Hedley DW. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res. 2005 Feb 15;65(4):1497-504. PubMed PMID: 15735038.

244: Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood. 2005 Jun 15;105(12):4759-66. Epub 2005 Feb 22. PubMed PMID: 15728126; PubMed Central PMCID: PMC1895008.

245: Ardavanis A, Tryfonopoulos D, Alexopoulos A, Kandylis C, Lainakis G, Rigatos G. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer. 2005 Feb 28;92(4):645-50. PubMed PMID: 15685232; PubMed Central PMCID: PMC2361881.

246: Miki T, Mikami K, Mizutani Y. [The second-line chemotherapy for urological cancers]. Gan To Kagaku Ryoho. 2005 Jan;32(1):33-8. Review. Japanese. PubMed PMID: 15675579.

247: Hanauske AR, Dittrich C, Otero J. Overview of phase I/II pemetrexed studies. Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):18-25. Review. PubMed PMID: 15655932.

248: Manabe T, Okino H, Maeyama R, Mizumoto K, Tanaka M, Matsuda T. New infusion device for trans-tissue, sustained local delivery of anticancer agent to surgically resected tissue: potential use for suppression of local recurrence of pancreatic cancer. J Biomed Mater Res B Appl Biomater. 2005 Apr;73(1):203-7. PubMed PMID: 15627244.

249: Krych M. [Acute renal failure]. Internist (Berl). 2005 Jan;46(1):30-8. Review. German. PubMed PMID: 15580461.

250: Park BH, Lee JH, Jeong JS, Rha SH, Kim SE, Kim JS, Kim JM, Hwang TH. Vascular administration of adenoviral vector soaked in absorbable gelatin sponge particles (GSP) prolongs the transgene expression in hepatocytes. Cancer Gene Ther. 2005 Feb;12(2):116-21. PubMed PMID: 15578067.

251: Immordino ML, Brusa P, Rocco F, Arpicco S, Ceruti M, Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J Control Release. 2004 Dec 10;100(3):331-46. PubMed PMID: 15567500.

252: Hsu CH, Liou JY, Dutschman GE, Cheng YC. Phosphorylation of Cytidine, Deoxycytidine, and Their Analog Monophosphates by Human UMP/CMP Kinase Is Differentially Regulated by ATP and Magnesium. Mol Pharmacol. 2005 Mar;67(3):806-14. Epub 2004 Nov 18. PubMed PMID: 15550676.

253: Kraemer K, Fuessel S, Kotzsch M, Ning S, Schmidt U, Wirth MP, Meye A. Chemosensitization of bladder cancer cell lines by human telomerase reverse transcriptase antisense treatment. J Urol. 2004 Nov;172(5 Pt 1):2023-8. PubMed PMID: 15540782.

254: Lopez CA, Kimchi ET, Mauceri HJ, Park JO, Mehta N, Murphy KT, Beckett MA, Hellman S, Posner MC, Kufe DW, Weichselbaum RR. Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther. 2004 Sep;3(9):1167-75. PubMed PMID: 15367711.

255: Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000. Drugs R D. 2004;5(5):305-11. PubMed PMID: 15357630.

256: Jordheim LP, Cros E, Gouy MH, Galmarini CM, Peyrottes S, Mackey J, Perigaud C, Dumontet C. Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug. Clin Cancer Res. 2004 Aug 15;10(16):5614-21. PubMed PMID: 15328204.

257: Ardavanis A, Tryfonopoulos D, Yiotis I, Gerasimidis G, Baziotis N, Rigatos G. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs. 2004 Jul;15(6):581-5. PubMed PMID: 15205600.

258: Alexopoulos A, Karamouzis MV, Rigatos G. In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: general concepts and future perspectives. Semin Oncol. 2004 Apr;31(2 Suppl 5):25-30. Review. PubMed PMID: 15199529.

259: Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol. 2004 Oct;54(4):343-53. Epub 2004 Jun 12. PubMed PMID: 15197486.

260: Pereira S, Fernandes PA, Ramos MJ. Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine. J Comput Chem. 2004 Jul 30;25(10):1286-94. PubMed PMID: 15139041.

261: Nakahara T, Sakaeda T, Nakamura T, Tamura T, Nishioka C, Aoyama N, Okamura N, Shirakawa T, Gotoh A, Kamigaki T, Ohno M, Kuroda Y, Matsuo M, Kasuga M, Okumura K. Chemosensitivity assessed by collagen gel droplet embedded culture drug sensitivity test, and MDR1, MRP1, and MRP2 mRNA expression in human colorectal adenocarcinomas. Pharm Res. 2004 Mar;21(3):406-12. PubMed PMID: 15070089.

262: July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther. 2004 Mar;3(3):223-32. PubMed PMID: 15026542.

263: Xu Y, Keith B, Grem JL. Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 5;802(2):263-70. PubMed PMID: 15018786.

264: Van Laar ES, Roth S, Weitman S, MacDonald JR, Waters SJ. Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo. Anticancer Res. 2004 Jan-Feb;24(1):59-65. PubMed PMID: 15015576.

265: Miura S, Izuta S. DNA polymerases as targets of anticancer nucleosides. Curr Drug Targets. 2004 Feb;5(2):191-5. Review. PubMed PMID: 15011952.

266: De Berardinis E, Antonini G, Peters GJ, Loves WJ, Van der Born K, Codacci-Pisanelli G, Di Silverio F. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU Int. 2004 Mar;93(4):491-4. PubMed PMID: 15008715.

267: Janmaat ML, Giaccone G. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc). 2003;39 Suppl C:61-80. Review. PubMed PMID: 14988746.

268: Gray JH, Mangravite LM, Owen RP, Urban TJ, Chan W, Carlson EJ, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, Giacomini KM. Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol. 2004 Mar;65(3):512-9. PubMed PMID: 14978229.

269: Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep. 2004 Mar;11(3):559-95. Review. PubMed PMID: 14767508.

270: Kakolyris S, Georgoulias V. The role of gemcitabine and paclitaxel as second-line chemotherapy for the treatment of advanced non small-cell lung cancer (NSCLC). Clin Lung Cancer. 2000 Aug;2(1):43-7. PubMed PMID: 14731336.

271: Loprevite M, Favoni RE, De Cupis A, Scolaro T, Semino C, Mazzanti P, Ardizzoni A. In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines. Oncol Rep. 2004 Feb;11(2):407-14. PubMed PMID: 14719076.

272: Armand JP. [Focus on cellular pharmacology of docetaxel]. Bull Cancer. 2003 Dec;90(12):1067-70. Review. French. PubMed PMID: 14715427.

273: Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas. 2004 Jan;28(1):38-44. PubMed PMID: 14707728.

274: Alexopoulos A, Tryfonopoulos D, Karamouzis MV, Gerasimidis G, Karydas I, Kandilis K, Stavrakakis J, Stavrinides H, Georganta C, Ardavanis A, Rigatos G. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Ann Oncol. 2004 Jan;15(1):95-9. PubMed PMID: 14679126.

275: Rosell R, Taron M, Camps C, López-Vivanco G. Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc). 2003 Oct;39(10):775-86. Review. PubMed PMID: 14668933.

276: Chen YM, Perng RP, Lee CS, Lin WC, Tsai CM, Whang-Peng J. Phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with non-small-cell lung cancer not responding to previous chemotherapy. Am J Clin Oncol. 2003 Dec;26(6):567-70. PubMed PMID: 14663373.

277: Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 2004 Feb 26;23(8):1539-48. PubMed PMID: 14661056.

278: Gmeiner WH, Yu S, Pon RT, Pourquier P, Pommier Y. Structural basis for topoisomerase I inhibition by nucleoside analogs. Nucleosides Nucleotides Nucleic Acids. 2003 May-Aug;22(5-8):653-8. Review. PubMed PMID: 14565246.

279: Ge Y, Jensen TL, Matherly LH, Taub JW. Physical and functional interactions between USF and Sp1 proteins regulate human deoxycytidine kinase promoter activity. J Biol Chem. 2003 Dec 12;278(50):49901-10. Epub 2003 Sep 26. PubMed PMID: 14514691.

280: Togawa A, Ito H, Kimura F, Shimizu H, Ohtsuka M, Shimamura F, Yoshidome H, Katoh A, Miyazaki M. Establishment of gemcitabine-resistant human pancreatic cancer cells and effect of brefeldin-a on the resistant cell line. Pancreas. 2003 Oct;27(3):220-4. PubMed PMID: 14508125.

281: Krasna L, Netikova I, Chaloupkova A, Taislova E, Zimovjanova M, Vesely P, Danes J, Petruzelka L, Matouskova E. Assessment of in vitro drug resistance of human breast cancer cells subcultured from biopsy specimens. Anticancer Res. 2003 May-Jun;23(3B):2593-9. PubMed PMID: 12894546.

282: Moore AS, Kitchell BE. New chemotherapy agents in veterinary medicine. Vet Clin North Am Small Anim Pract. 2003 May;33(3):629-49, viii. Review. PubMed PMID: 12852240.

283: Adis International Ltd. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415. Drugs R D. 2003;4(4):243-8. PubMed PMID: 12848590.

284: Lin MH, Chen JS, Chen HH, Su WC. A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy. 2003 Jun;49(3):154-8. PubMed PMID: 12815209.

285: Ostruszka LJ, Shewach DS. The role of DNA synthesis inhibition in the cytotoxicity of 2',2'-difluoro-2'-deoxycytidine. Cancer Chemother Pharmacol. 2003 Oct;52(4):325-32. Epub 2003 Jun 17. PubMed PMID: 12811514.

286: Sabini E, Ort S, Monnerjahn C, Konrad M, Lavie A. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol. 2003 Jul;10(7):513-9. PubMed PMID: 12808445.

287: Miyazaki J, Kawai K. [Prevention and management of nephrotoxicity from anti-cancer agents]. Nippon Rinsho. 2003 Jun;61(6):973-7. Review. Japanese. PubMed PMID: 12806945.

288: Fedier A, Schlamminger M, Schwarz VA, Haller U, Howell SB, Fink D. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Ann Oncol. 2003 Jun;14(6):938-45. PubMed PMID: 12796033.

289: Kanzawa F, Akiyama Y, Saijo N, Nishio K. In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line. Lung Cancer. 2003 Jun;40(3):325-32. PubMed PMID: 12781432.

290: Wataru K. [Prospects for standardization of surgical procedures for carcinoma of the pancreas]. Nippon Geka Gakkai Zasshi. 2003 May;104(5):412-21. Review. Japanese. PubMed PMID: 12774526.

291: Marimastat: BB 2516, TA 2516. Drugs R D. 2003;4(3):198-203. Review. PubMed PMID: 12757409.

292: Aydemir N, Bilaloğlu R. Genotoxicity of two anticancer drugs, gemcitabine and topotecan, in mouse bone marrow in vivo. Mutat Res. 2003 May 9;537(1):43-51. PubMed PMID: 12742506.

293: Kawamata O, Uda M, Mori M, Urakubo N, Hamano R, Oota T. [Gemcitabine improved QOL and survival in a case of diffuse malignant pleural mesothelioma]. Gan To Kagaku Ryoho. 2003 Apr;30(4):551-4. Japanese. PubMed PMID: 12722691.

294: Mahboobi H, Viarengo A, Colangelo D, Osella D. Effect of metal-based anticancer drugs on wild type and metallothionein null cell lines. Biometals. 2003 Sep;16(3):403-9. PubMed PMID: 12680702.

295: Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol. 2003 May;22(5):1169-73. PubMed PMID: 12684687.

296: Medina-Gundrum L, Cerna C, Gomez LR, Yochmowitz M, Weitman S. AMD473 (ZD0473) exhibits marked in vitro anticancer activity in human tumor specimens taken directly from patients. Anticancer Drugs. 2003 Apr;14(4):275-80. PubMed PMID: 12679731.

297: Feng N, Jin H, Wang M, Du C, Wright JA, Young AH. Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts. Cancer Chemother Pharmacol. 2003 Mar;51(3):247-55. Epub 2003 Mar 5. PubMed PMID: 12655444.

298: Scheithauer W. Review of gemcitabine in biliary tract carcinoma. Semin Oncol. 2002 Dec;29(6 Suppl 20):40-5. Review. PubMed PMID: 12577232.

299: Ugurel S, Tilgen W, Reinhold U. Chemosensitivity testing in malignant melanoma. Recent Results Cancer Res. 2003;161:81-92. PubMed PMID: 12528801.

300: Sun FX, Tohgo A, Bouvet M, Yagi S, Nassirpour R, Moossa AR, Hoffman RM. Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res. 2003 Jan 1;63(1):80-5. PubMed PMID: 12517781.

301: Geffen DB, Man S. New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31. Review. PubMed PMID: 12516906.

302: Clarke ML, Mackey JR, Baldwin SA, Young JD, Cass CE. The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat Res. 2002;112:27-47. Review. PubMed PMID: 12481710.

303: Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002 Jan;1(3):227-35. Review. PubMed PMID: 12467217.

304: Yamada T, Roppongi T, Maemura M, Fujii T, Takeyoshi I, Ohwada S, Morishita Y. [A case of pancreatic tail cancer with peritoneal carcinosis treated with gemcitabine hydrochloride]. Gan To Kagaku Ryoho. 2002 Nov;29(11):1977-80. Japanese. PubMed PMID: 12465399.

305: McMullen KP, Blackstock AW. Chemoradiation with novel agents for rectal cancer. Clin Colorectal Cancer. 2002 May;2(1):24-30. Review. PubMed PMID: 12453333.

306: Fedier A, Ruefenacht UB, Schwarz VA, Haller U, Fink D. Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2. Br J Cancer. 2002 Oct 21;87(9):1027-33. PubMed PMID: 12434296; PubMed Central PMCID: PMC2364320.

307: Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol. 2002 Oct;29(5 Suppl 14):55-60. Review. PubMed PMID: 12422314.

308: Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, Bares R. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1462-9. Epub 2002 Sep 6. PubMed PMID: 12397465.

309: Caponigro F. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002. Anticancer Drugs. 2002 Sep;13(8):891-7. PubMed PMID: 12394276.

310: Keyes K, Cox K, Treadway P, Mann L, Shih C, Faul MM, Teicher BA. An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res. 2002 Oct 1;62(19):5597-602. PubMed PMID: 12359773.

311: Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis. 2002 Oct;40(4):E16. Review. PubMed PMID: 12324937.

312: Roychowdhury DF, Cassidy CA, Peterson P, Arning M. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs. 2002 Aug;20(3):311-5. PubMed PMID: 12201493.

313: Rogers P, Boxall FE, Allott CP, Stephens TC, Kelland LR. Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Eur J Cancer. 2002 Aug;38(12):1653-60. PubMed PMID: 12142057.

314: Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, Okumura K. Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull. 2002 Jun;25(6):771-8. PubMed PMID: 12081145.

315: Bokemeyer C, Hartmann JT, Kuczyk MA, Truss MC, Kollmannsberger C, Beyer J, Jonas U, Kanz L. Recent strategies for the use of paclitaxel in the treatment of urological malignancies. World J Urol. 1998;16(2):155-62. Review. PubMed PMID: 12073232.

316: Kindler HL. Malignant pleural mesothelioma. Curr Treat Options Oncol. 2000 Oct;1(4):313-26. Review. PubMed PMID: 12057157.

317: Beauséjour CM, Gagnon J, Primeau M, Momparler RL. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. Biochem Biophys Res Commun. 2002 May 24;293(5):1478-84. PubMed PMID: 12054682.

318: Saga Y, Mizukami H, Suzuki M, Kohno T, Urabe M, Ozawa K, Sato I. Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells. Clin Cancer Res. 2002 May;8(5):1248-52. PubMed PMID: 12006545.

319: Georgoulias V. Docetaxel (taxotere) in the treatment of non-small cell lung cancer. Curr Med Chem. 2002 Apr;9(8):869-77. PubMed PMID: 11966449.

320: Di Stefano G, Lanza M, Busi C, Barbieri L, Fiume L. Conjugates of nucleoside analogs with lactosaminated human albumin to selectively increase the drug levels in liver blood: requirements for a regional chemotherapy. J Pharmacol Exp Ther. 2002 May;301(2):638-42. PubMed PMID: 11961068.

321: Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K, Gallo JM. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol. 2002 Apr 1;63(7):1219-28. PubMed PMID: 11960598.

322: Okada S. [Radiotherapy and chemotherapy for unresectable pancreatic cancer]. Gan To Kagaku Ryoho. 2002 Mar;29(3):376-82. Review. Japanese. PubMed PMID: 11915726.

323: Saga Y, Suzuki M, Machida S, Ohwada M, Sato I. Establishment of a new cell line (TAYA) of clear cell adenocarcinoma of the ovary and its radiosensitivity. Oncology. 2002;62(2):180-4. PubMed PMID: 11914605.

324: Liou JY, Dutschman GE, Lam W, Jiang Z, Cheng YC. Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates. Cancer Res. 2002 Mar 15;62(6):1624-31. PubMed PMID: 11912132.

325: Schwartsmann G, Brondani da Rocha A, Berlinck RG, Jimeno J. Marine organisms as a source of new anticancer agents. Lancet Oncol. 2001 Apr;2(4):221-5. Review. PubMed PMID: 11905767.

326: Joerger M, Gunz A, Speich R, Pestalozzi BC. Gemcitabine-related pulmonary toxicity. Swiss Med Wkly. 2002 Jan 12;132(1-2):17-20. PubMed PMID: 11901447.

327: Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res. 2002 Mar;8(3):878-84. PubMed PMID: 11895922.

328: Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res. 2002 Feb;8(2):555-65. PubMed PMID: 11839677.

329: Mori T, Ohnishi M, Komiyama M, Tsutsui A, Yabushita H, Okada H. Prediction of cell kill kinetics of anticancer agents using the collagen gel droplet embedded-culture drug sensitivity test. Oncol Rep. 2002 Mar-Apr;9(2):301-5. PubMed PMID: 11836596.

330: Konerding D, James TL, Trump E, Soto AM, Marky LA, Gmeiner WH. NMR structure of a gemcitabine-substituted model Okazaki fragment. Biochemistry. 2002 Jan 22;41(3):839-46. PubMed PMID: 11790105.

331: Bécouarn Y, Agostini C, Trufflandier N, Boulanger V. Oxaliplatin: available data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol. 2001 Dec;40(3):265-72. Review. PubMed PMID: 11738949.

332: Guo Zw Z, Gallo JM. Selective Protection of 2',2'-Difluorodeoxycytidine (Gemcitabine). J Org Chem. 1999 Oct 29;64(22):8319-8322. PubMed PMID: 11674754.

333: Guo P, Ma J, Li S, Guo Z, Adams AL, Gallo JM. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. Cancer Chemother Pharmacol. 2001 Aug;48(2):169-76. PubMed PMID: 11561783.

334: Inoue A, Saijo N. Recent advances in the chemotherapy of non-small cell lung cancer. Jpn J Clin Oncol. 2001 Jul;31(7):299-304. Review. PubMed PMID: 11518741.

335: Perello L, Demirdjian S, Dory A, Bourget P. Application of high-performance, thin-layer chromatography to quality control of antimetabolite analogue infusion bags. J AOAC Int. 2001 Jul-Aug;84(4):1296-300. PubMed PMID: 11501935.

336: Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PW, Lee JE, Janjan NA, Charnsangavej C, Abbruzzese JL. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res. 2001 Aug;7(8):2246-53. PubMed PMID: 11489798.

337: Shih C, Teicher BA. Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides. Curr Pharm Des. 2001 Sep;7(13):1259-76. Review. PubMed PMID: 11472266.

338: Lee NC, Bouvet M, Nardin S, Jiang P, Baranov E, Rashidi B, Yang M, Wang X, Moossa AR, Hoffma RM. Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model. Clin Exp Metastasis. 2000;18(5):379-84. PubMed PMID: 11467769.

339: Martino R, Malet-Martino M, Gilard V. Fluorine nuclear magnetic resonance, a privileged tool for metabolic studies of fluoropyrimidine drugs. Curr Drug Metab. 2000 Nov;1(3):271-303. Review. PubMed PMID: 11465049.

340: Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology. 2001 May-Jun;48(39):783-9. PubMed PMID: 11462924.

341: Cappella P, Tomasoni D, Faretta M, Lupi M, Montalenti F, Viale F, Banzato F, D'Incalci M, Ubezio P. Cell cycle effects of gemcitabine. Int J Cancer. 2001 Aug 1;93(3):401-8. PubMed PMID: 11433406.

342: Loprevite M, Favoni RE, de Cupis A, Pirani P, Pietra G, Bruno S, Grossi F, Scolaro T, Ardizzoni A. Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines. Lung Cancer. 2001 Jul;33(1):27-39. PubMed PMID: 11429193.

343: Smid K, Van Moorsel CJ, Noordhuis P, Voorn DA, Peters GJ. Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay. Int J Oncol. 2001 Jul;19(1):157-62. PubMed PMID: 11408937.

344: Briasoulis E, Pavlidis N. Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist. 2001;6(2):153-61. Review. PubMed PMID: 11306727.

345: Rosell R, Sánchez JM, Tarón M, O'Brate A, Gutiérrez JL, Monzó M, Felip E, Sánchez JJ, Alberola V. Novel approaches in the treatment of non-small-cell lung cancer. Oncology (Williston Park). 2001 Mar;15(3 Suppl 6):52-60. Review. PubMed PMID: 11301850.

346: Keyes KA, Segovia JC, Bueren JA, Parchment RE, Albella B. Latent hematopoietic stem cell toxicity associated with protracted drug administration. Exp Hematol. 2001 Mar;29(3):286-94. PubMed PMID: 11274755.

347: Azuma A, Huang P, Matsuda A, Plunkett W. 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Mol Pharmacol. 2001 Apr;59(4):725-31. PubMed PMID: 11259616.

348: Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001 Jan;24(1):19-38. Review. PubMed PMID: 11219485.

349: Li J, Zheng LM, King I, Doyle TW, Chen SH. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs. Curr Med Chem. 2001 Feb;8(2):121-33. Review. PubMed PMID: 11172670.

350: Jiang HY, Hickey RJ, Abdel-Aziz W, Malkas LH. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome. Cancer Chemother Pharmacol. 2000;45(4):320-8. PubMed PMID: 10755321.

351: Ferreira CG, Span SW, Peters GJ, Kruyt FA, Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res. 2000 Dec 15;60(24):7133-41. PubMed PMID: 11156422.

352: Nielsen LL, Gurnani M, Shi B, Terracina G, Johnson RC, Carroll J, Mathis JM, Hajian G. Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics. Cancer Res. 2000 Dec 15;60(24):7066-74. PubMed PMID: 11156413.

353: Ogawa M. Current Status and Perspectives in Cancer Chemotherapy. Breast Cancer. 1999 Oct 25;6(4):270-274. PubMed PMID: 11091728.

354: Kobayashi K, Kobayashi T. [Outpatient clinic in Saitama Cancer Center]. Gan To Kagaku Ryoho. 2000 Oct;27(11):1656-61. Review. Japanese. PubMed PMID: 11057315.

355: Padrón JM, van der Wilt CL, Smid K, Smitskamp-Wilms E, Backus HH, Pizao PE, Giaccone G, Peters GJ. The multilayered postconfluent cell culture as a model for drug screening. Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):141-57. Review. PubMed PMID: 11033303.

356: Lostao MP, Mata JF, Larrayoz IM, Inzillo SM, Casado FJ, Pastor-Anglada M. Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes. FEBS Lett. 2000 Sep 15;481(2):137-40. PubMed PMID: 10996312.

357: Wexler EJ, Gravallese EM, Czerniak PM, Devenny JJ, Longtine J, Wong MK, Slee AM, Kerr JS. Tumor biology: use of tiled images in conjunction with measurements of cellular proliferation and death in response to drug treatments. Clin Cancer Res. 2000 Aug;6(8):3361-70. PubMed PMID: 10955824.

358: Trimble EL. Innovative therapies for advanced ovarian cancer. Semin Oncol. 2000 Jun;27(3 Suppl 7):24-30. Review. PubMed PMID: 10952123.

359: Sone S. [Clinical development of new molecular targeted therapeutics for cancer therapy]. Gan To Kagaku Ryoho. 2000 Jul;27(8):1117-26. Review. Japanese. PubMed PMID: 10945005.

360: Mercié P, Faure I, Viallard JF, Demeaux H, Dilhuydy MS, Leng B, Pellegrin JL. [Splenic vascular occlusion in the course of pancreatic cancer]. Rev Med Interne. 2000 Jul;21(7):628-31. French. PubMed PMID: 10942980.

361: Gross M, Hiesse C, Kriaa F, Goldwasser F. Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine. Anticancer Drugs. 1999 Jul;10(6):533-6. PubMed PMID: 10885900.

362: Keyes KA, Albella B, LoRusso PM, Bueren JA, Parchment RE. Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond. Clin Cancer Res. 2000 Jun;6(6):2474-81. PubMed PMID: 10873102.

363: Barret JM, Etiévant C, Hill BT. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol. 2000;45(6):471-6. PubMed PMID: 10854134.

364: Feng L, Achanta G, Pelicano H, Zhang W, Plunkett W, Huang P. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. Int J Mol Med. 2000 Jun;5(6):597-604. PubMed PMID: 10812007.

365: Nakao M, Nomoto T, Mizutani Y, Miki T. [Salvage chemotherapy in refractory testicular cancer]. Gan To Kagaku Ryoho. 2000 Apr;27(4):542-7. Review. Japanese. PubMed PMID: 10790996.

366: Pacini S, Milano F, Pinzani P, Pazzagli M, Gulisano M, Ruggiero M, Casamassima F. Effects of gemcitabine in normal and transformed human lung cell cultures: cytotoxicity and increase in radiation sensitivity. Tumori. 1999 Nov-Dec;85(6):503-7. PubMed PMID: 10774574.

367: Yang LY, Li L, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res. 2000 Mar;6(3):773-81. PubMed PMID: 10741696.

368: Bahadori HR, Rocha Lima CM, Green MR, Safa AR. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines. Anticancer Res. 1999 Nov-Dec;19(6B):5423-8. PubMed PMID: 10697572.

369: Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng Y, Sartorelli AC. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem Pharmacol. 2000 Apr 15;59(8):983-91. PubMed PMID: 10692563.

370: Liu P, Menon K, Alvarez E, Lu K, Teicher BA. Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo. Int J Oncol. 2000 Mar;16(3):599-610. PubMed PMID: 10675495.

371: Kraus-Berthier L, Jan M, Guilbaud N, Naze M, Pierré A, Atassi G. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin Cancer Res. 2000 Jan;6(1):297-304. PubMed PMID: 10656461.

372: Ferreira CG, Tolis C, Span SW, Peters GJ, van Lopik T, Kummer AJ, Pinedo HM, Giaccone G. Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res. 2000 Jan;6(1):203-12. PubMed PMID: 10656451.

373: Kelland LR. Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. J Inorg Biochem. 1999 Oct;77(1-2):121-4. PubMed PMID: 10626364.

374: Lhotta K, Kühr T, Rumpelt HJ, Wöll E, Thaler J, König P. Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy. Am J Nephrol. 1999;19(5):590-3. PubMed PMID: 10575189.

375: Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, Young JD. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst. 1999 Nov 3;91(21):1876-81. PubMed PMID: 10547395.

376: Kreil A, Bauer J, Scheithauer W. [In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma]. Acta Med Austriaca. 1999;26(3):93-100. German. PubMed PMID: 10520377.

377: Hortobagyi GN, Hung MC, Buzdar AU. Recent developments in breast cancer therapy. Semin Oncol. 1999 Aug;26(4 Suppl 12):11-20. Review. PubMed PMID: 10482190.

378: Padrón JM, van Moorsel CJ, Bergman AM, Smitskamp-Wilms E, van der Wilt CL, Peters GJ. Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures. Anticancer Drugs. 1999 Jun;10(5):445-52. PubMed PMID: 10477163.

379: Beinert T, Binder D, Oehm C, Ziemer S, Priem F, Schweigert M, Stuschke M, Fleischhacker M, Siebert G, Mergenthaler HG, Werner TG, Sezer O, Possinger K. Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy? Eur J Med Res. 1999 Aug 25;4(8):328-34. PubMed PMID: 10471544.

380: van Groeningen CJ. Intravenous and intra-arterial chemotherapeutic possibilities in biliopancreatic cancer. Ann Oncol. 1999;10 Suppl 4:305-7. Review. PubMed PMID: 10436846.

381: Decosterd LA, Cottin E, Chen X, Lejeune F, Mirimanoff RO, Biollaz J, Coucke PA. Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high-performance liquid chromatography. Anal Biochem. 1999 May 15;270(1):59-68. PubMed PMID: 10328765.

382: Barton-Burke M. Gemcitabine: a pharmacologic and clinical overview. Cancer Nurs. 1999 Apr;22(2):176-83. Review. PubMed PMID: 10217035.

383: Pestieau SR, Stuart OA, Chang D, Jacquet P, Sugarbaker PH. Pharmacokinetics of intraperitoneal gemcitabine in a rat model. Tumori. 1998 Nov-Dec;84(6):706-11. PubMed PMID: 10080682.

384: Cartee L, Kucera GL, Nixon JB. The effects of gemcitabine and TPA on PKC signaling in BG-1 human ovarian cancer cells. Oncol Res. 1998;10(7):371-7. PubMed PMID: 10063971.

385: Cottu PH, Extra JM, Lerebours F, Espie M, Marty M. [Clinical activity spectrum of irinotecan]. Bull Cancer. 1998 Dec;Spec No:21-5. Review. French. PubMed PMID: 9932080.

386: Lichtman SM. Recent developments in the pharmacology of anticancer drugs in the elderly. Curr Opin Oncol. 1998 Nov;10(6):572-9. Review. PubMed PMID: 9818238.

387: Touroutoglou N, Gravel D, Raber MN, Plunkett W, Abbruzzese JL. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol. 1998 Sep;9(9):1003-8. PubMed PMID: 9818075.

388: Von Hoff DD. There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res. 1998 May;4(5):1079-86. PubMed PMID: 9607564.

389: Stephens CD. Gemcitabine: a new approach to treating pancreatic cancer. Oncol Nurs Forum. 1998 Jan-Feb;25(1):87-93. Review. PubMed PMID: 9460776.

390: Klastersky J, Awada A. [Gemcitabine: a new chemotherapy agent for solid cancers]. Rev Med Brux. 1997 Oct;18(5):328-34. Review. French. PubMed PMID: 9441329.

391: Noble S, Goa KL. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs. 1997 Sep;54(3):447-72. Review. PubMed PMID: 9279506.

392: Huang P, Ballal K, Plunkett W. Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis. Cancer Res. 1997 Aug 15;57(16):3407-14. PubMed PMID: 9270006.

393: Martin C, Ardizzoni A, Rosso R. Gemcitabine: safety profile and efficacy in non-small cell lung cancer unaffected by age. Aging (Milano). 1997 Aug;9(4):297-303. PubMed PMID: 9359941.

394: Cortes-Funes H, Martin C, Abratt R, Lund B. Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer. Anticancer Drugs. 1997 Jul;8(6):582-7. PubMed PMID: 9300572.

395: Armand JP. New anticancer drugs in Europe. Gan To Kagaku Ryoho. 1997 May;24 Suppl 1:70-93. Review. PubMed PMID: 9210890.

396: Tashiro T. [Acquisition of resistance associated with impairment of metabolic activation of anticancer drugs]. Nippon Rinsho. 1997 May;55(5):1038-43. Review. Japanese. PubMed PMID: 9155149.

397: van Moorsel CJ, Veerman G, Bergman AM, Guechev A, Vermorken JB, Postmus PE, Peters GJ. Combination chemotherapy studies with gemcitabine. Semin Oncol. 1997 Apr;24(2 Suppl 7):S7-17-S7-23. Review. PubMed PMID: 9194475.

398: Kanzawa F, Saijo N. In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol. 1997 Apr;24(2 Suppl 7):S7-8-S7-16. PubMed PMID: 9194474.

399: Mani S, Ratain MJ. Promising new agents in oncologic treatment. Curr Opin Oncol. 1996 Nov;8(6):525-34. Review. PubMed PMID: 8971473.

400: Fukuoka M, Negoro S, Kudo S, Furuse K, Nishikawa H, Takada Y, Kamei T, Niitani H, Taguchi T. [Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)]. Gan To Kagaku Ryoho. 1996 Nov;23(13):1825-32. Japanese. PubMed PMID: 8937493.

401: Shewach DS, Lawrence TS. Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol. 1996 Oct;23(5 Suppl 10):65-71. Review. PubMed PMID: 8893885.

402: Hanauske AR. The development of new chemotherapeutic agents. Anticancer Drugs. 1996 Aug;7 Suppl 2:29-32. Review. PubMed PMID: 8862708.

403: Martin C, Lund B, Anderson H, Thatcher N. Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule. Anticancer Drugs. 1996 May;7(3):351-7. Review. PubMed PMID: 8792011.

404: van Haperen VW, Veerman G, Vermorken JB, Pinedo HM, Peters G. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine. Biochem Pharmacol. 1996 Apr 12;51(7):911-8. PubMed PMID: 8651941.

405: Martin C, Pollera CF. Gemcitabine: safety profile unaffected by starting dose. Int J Clin Pharmacol Res. 1996;16(1):9-18. PubMed PMID: 9001925.

406: Verweij J. New promising anticancer agents in development: what comes next? Cancer Chemother Pharmacol. 1996;38 Suppl:S3-10. Review. PubMed PMID: 8765408.

407: Schellens JH, Pronk LC, Verweij J. Emerging drug treatments for solid tumours. Drugs. 1996 Jan;51(1):45-72. Review. PubMed PMID: 8741232.

408: Eckardt J, Eckhardt G, Villalona-Calero M, Drengler R, Von Hoff D. New anticancer agents in clinical development. Oncology (Williston Park). 1995 Dec;9(12):1321-8; 1331; discussion 1332-4. Review. PubMed PMID: 8771106.

409: Eckardt J, Eckhardt G, Villalona-Calero M, Drengler R, Von Hoff D. New anticancer agents in clinical development. Oncology (Williston Park). 1995 Nov;9(11):1191-9. Review. PubMed PMID: 8703688.

410: Huang P, Robertson LE, Wright S, Plunkett W. High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells. Clin Cancer Res. 1995 Sep;1(9):1005-13. PubMed PMID: 9816073.

411: Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995 Aug;22(4 Suppl 11):3-10. Review. PubMed PMID: 7481842.

412: Giaccone G. New drugs in non-small cell lung cancer. An overview. Lung Cancer. 1995 Apr;12 Suppl 1:S155-62. Review. PubMed PMID: 7551924.

413: Masuda N. [Phase III trial of new anticancer agents from a medical oncologists viewpoint]. Gan To Kagaku Ryoho. 1995 Feb;22(3):313-8. Review. Japanese. PubMed PMID: 7880100.

414: Ariyoshi Y, Sugiura T. [New promising anticancer drugs for lung cancer]. Gan To Kagaku Ryoho. 1994 Nov;21(15):2578-84. Review. Japanese. PubMed PMID: 7979416.

415: Weiss GR, Burris HA 3rd, Eckardt JR, Fields S, O'Rourke T, Rodriguez GI, Rothenberg ML. New anticancer agents. Cancer Chemother Biol Response Modif. 1994;15:130-51. Review. PubMed PMID: 7779583.

416: Mertens WC, Eisenhauer EA, Moore M, Venner P, Stewart D, Muldal A, Wong D. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1993 Apr;4(4):331-2. PubMed PMID: 8518225.

417: Schultz RM, Merriman RL, Toth JE, Zimmermann JE, Hertel LW, Andis SL, Dudley DE, Rutherford PG, Tanzer LR, Grindey GB. Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res. 1993;5(6-7):223-8. PubMed PMID: 8123942.

418: Huang P, Plunkett W. A quantitative assay for fragmented DNA in apoptotic cells. Anal Biochem. 1992 Nov 15;207(1):163-7. PubMed PMID: 1489090.

419: Brown TD, Burris HA, Havlin KA, O'Rourke TJ, Rodriguez GI, Wall JG, Weiss GR. New anticancer agents. Cancer Chemother Biol Response Modif. 1991;12:111-46. Review. PubMed PMID: 1718374.